- Home
- ACRS vs NPV Comparison
ACRS vs NPV Comparison
Compare ACRS & NPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- NPV
- Stock Information
- Founded
- ACRS 2012
- NPV 1993
- Country
- ACRS United States
- NPV United States
- Employees
- ACRS N/A
- NPV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- NPV Investment Managers
- Sector
- ACRS Health Care
- NPV Finance
- Exchange
- ACRS Nasdaq
- NPV Nasdaq
- Market Cap
- ACRS 198.2M
- NPV 211.4M
- IPO Year
- ACRS 2015
- NPV N/A
- Fundamental
- Price
- ACRS $2.26
- NPV $11.49
- Analyst Decision
- ACRS Strong Buy
- NPV
- Analyst Count
- ACRS 9
- NPV 0
- Target Price
- ACRS $9.25
- NPV N/A
- AVG Volume (30 Days)
- ACRS 1.5M
- NPV 38.9K
- Earning Date
- ACRS 11-06-2025
- NPV 01-01-0001
- Dividend Yield
- ACRS N/A
- NPV 3.90%
- EPS Growth
- ACRS N/A
- NPV N/A
- EPS
- ACRS N/A
- NPV N/A
- Revenue
- ACRS $16,789,000.00
- NPV N/A
- Revenue This Year
- ACRS N/A
- NPV N/A
- Revenue Next Year
- ACRS N/A
- NPV N/A
- P/E Ratio
- ACRS N/A
- NPV N/A
- Revenue Growth
- ACRS N/A
- NPV N/A
- 52 Week Low
- ACRS $1.05
- NPV $8.92
- 52 Week High
- ACRS $5.17
- NPV $11.55
- Technical
- Relative Strength Index (RSI)
- ACRS 53.36
- NPV 53.69
- Support Level
- ACRS $2.24
- NPV $11.42
- Resistance Level
- ACRS $2.70
- NPV $11.58
- Average True Range (ATR)
- ACRS 0.23
- NPV 0.10
- MACD
- ACRS 0.01
- NPV -0.00
- Stochastic Oscillator
- ACRS 46.34
- NPV 64.28
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.